10-K: Verastem Oncology Reports Progress in LGSOC, Pancreatic Cancer, and NSCLC Programs; Announces 2024 Financial Results

Verastem Oncology highlights FDA priority review for avutometinib plus defactinib in KRAS mutant recurrent LGSOC and advancements in other pipeline programs alongside its 2024 financial results.

Summary

• Verastem Oncology reported its fourth quarter and full-year 2024 financial results, highlighting key advancements in its pipeline programs.
• The FDA granted priority review for the NDA of avutometinib plus defactinib for KRAS mutant recurrent LGSOC, setting a PDUFA action date of June 30, 2025.
• A confirmatory Phase 3 trial (RAMP 301) is underway for recurrent LGSOC, with enrollment expected to complete by the end of 2025.
• A Phase 2 trial (RAMP 201J) evaluating the safety and efficacy of avutometinib in combination with defactinib for recurrent LGSOC in Japan is underway, with initial data expected in H2 2025.
• The RAMP 205 trial in first-line metastatic pancreatic cancer continues to progress, with enrollment across all dose-level cohorts on track to complete in Q1.
• The Company is planning to initiate a Phase 1/2a study for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in the U.S. by mid-2025.
• The Company reported cash, cash equivalents, and investments of $88.8 million as of December 31, 2024, and a pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market facility.
• Total operating expenses for 2024 were $125.0 million, with a net loss of $130.6 million, or $3.66 per share.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with key regulatory milestones achieved and promising clinical data. However, the company is still loss making and dependent on future regulatory approvals and commercial success.

Positives

• The FDA granted priority review for the NDA of avutometinib plus defactinib for KRAS mutant recurrent LGSOC, with a PDUFA action date of June 30, 2025.
• The RAMP 201 study showed clinically meaningful responses in patients with and without prior MEK inhibitor treatment, with and without prior bevacizumab treatment, as well as patients receiving multiple lines of therapy.
• The RAMP 301 trial, which is currently enrolling patients with recurrent LGSOC regardless of KRAS mutation status, will serve as a confirmatory study for the initial indication and has potential to expand the indication regardless of KRAS mutation status.
• The Company is planning to initiate a Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in the U.S. by mid-2025.

Negatives

• The Company reported a net loss of $130.6 million, or $3.66 per share, for the year ended December 31, 2024.

Risks

• The success of the Company's product candidates is subject to the uncertainties inherent in research and development, such as the possibility of negative or unexpected results of clinical trials.
• The Company may not see a return on investment on the payments it has and may continue to make pursuant to the collaboration and option agreement with GenFleet, or that GenFleet may fail to fully perform under the agreement.
• The development and commercialization of the Company's product candidates may take longer or cost more than planned, including as a result of conducting additional studies or the Company's decisions regarding execution of such commercialization.
• The Company's product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Future Outlook

Verastem anticipates a potential launch of the first FDA-approved treatment specifically for KRAS mutant recurrent low-grade serous ovarian cancer and becoming a fully integrated commercial-stage company in 2025. The Company also expects to advance its pipeline programs in pancreatic cancer and non-small cell lung cancer and initiate a Phase 1/2a study for VS-7375.

Management Comments

• In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of avutometinib plus defactinib for Priority Review under the accelerated approval pathway for KRAS mutant recurrent low-grade serous ovarian cancer, said Dan Paterson, president and chief executive officer of Verastem Oncology.
• 2025 is expected to be a transformational year with our potential to launch the first FDA-approved treatment specifically for KRAS mutant recurrent low-grade serous ovarian cancer and become a fully integrated commercial-stage company. In addition, we anticipate advancing our pipeline programs in pancreatic cancer and non-small cell lung cancer and expect to initiate a Phase 1/2a study for VS-7375, our recently licensed KRAS G12D (ON/OFF) inhibitor.

Industry Context

The announcement reflects the ongoing efforts in the biopharmaceutical industry to develop targeted therapies for cancers driven by RAS/MAPK pathway mutations, particularly KRAS mutations, which have historically been difficult to target. The progress in LGSOC, pancreatic cancer, and NSCLC aligns with the broader trend of personalized medicine and combination therapies to improve patient outcomes.

Comparison to Industry Standards

• The 44% ORR in KRAS mutant LGSOC patients in the RAMP 201 study compares favorably to historical response rates of 6%-13% with standard of care treatments.
• The median duration of response of 31.1 months in all evaluable patients in the RAMP 201 study is a significant improvement over existing therapies.
• The addition of defactinib to sotorasib and avutometinib in the RAMP 203 study is consistent with the industry trend of combining multiple agents to overcome resistance mechanisms and improve efficacy in KRAS G12C-mutant NSCLC.
• The 83% ORR in the dose level 1 cohort of the RAMP 205 study in first-line metastatic pancreatic cancer is promising compared to historical response rates with standard chemotherapy regimens.

Management Changes

Stakeholder Impact

• Positive impact on patients with RAS/MAPK pathway-driven cancers, particularly LGSOC, pancreatic cancer, and NSCLC, through the development of new treatment options.
• Potential for increased shareholder value through successful commercialization of product candidates and achievement of milestones.
• Continued employment opportunities for employees involved in research, development, and commercialization activities.

Next Steps

• Plan for FDA decision on NDA submitted for the combination of avutometinib plus defactinib in KRAS mutant recurrent LGSOC, expected by June 30, 2025.
• Plan to submit for NCCN guideline inclusion upon FDA approval.
• Complete enrollment for the international Phase 3 confirmatory RAMP 301 clinical trial for patients with recurrent LGSOC regardless of KRAS mutation status by the end of 2025.
• Report initial data from the RAMP 201J Phase 2 clinical trial being conducted in Japan with JGOG in H2 2025.
• Continue to advance the regulatory pathway in Japan and Europe.
• Present additional data from the RAMP 205 trial at a medical meeting mid-year 2025.
• Select the recommended Phase 2 Dose (RP2D) for trial expansion in H1 2025.
• Plan to present an interim update of both doublet and triplet data from the RAMP 203 trial at a medical meeting in H2 2025.
• Initiate a Phase 1/2a trial for VS-7375 in the U.S. by mid-2025.
• Share preclinical and clinical data from the Phase 1 study of VS-7375 in China in H1 2025.

Key Dates

Keywords

Avutometinib, Defactinib, LGSOC, KRAS, Pancreatic Cancer, NSCLC, VS-7375, GenFleet, RAMP 201, RAMP 301, RAMP 205, RAMP 203, FDA, Oncology, Pharmaceutical